UCB SA (UCB.BR) Stock
UCB SA

Company profile
UCB SA reported revenue of 7.74 billion EUR for fiscal year 2025, and net income of 1.56 billion EUR. That is a net profit margin of 20.1% for fiscal year 2025. Our analysis of its filings shows revenue growing from 5.25 billion EUR in fiscal year 2023 to 7.74 billion EUR in fiscal year 2025, 21.4% a year on average. UCB SA reports about 9,000 full-time employees.
What stands out
- Revenue rose 25.8% in fiscal year 2025, from 6.15 billion EUR in fiscal year 2024, after a rise of 17.1% the year before.
- The United States brought in 63% of revenue by region in fiscal year 2025, up from 54% in fiscal year 2024; the company is based in Belgium.
- It spent 1.82 billion EUR on research and development in fiscal year 2025, 23.5% of its revenue.
Figures from company filings; latest fiscal year ended December 31, 2025.
About UCB SA
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson's disease and restless legs syndrome. It also provides Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. In addition, the company offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx to treat plaque psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; Fintepla for the treatment of Dravet and Lennox-Gastaut syndrome; and RYSTIGGO and ZILBRYSQ to treat people living with generalized myasthenia gravis. Further, it develops KYGEVVI (doxecitine/doxribtimine) for thymidine kinase 2 deficiency disorder; fenfluramine to treat CDKL5 deficiency disorder, and RETT-Syndrome; dapirolizumab pegol for systemic lupus erythematosus; STACCATO alprazolam for treating stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; and UCB9741 for atopic dermatitis, non cystic fibrosis bronchiectasis, and chronic obstructive pulmonary disease. Additionally, it engages in the contract manufacturing activities. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
Largest shareholders
- FinancièRe De Tubize S.A.36.28%
- Ucb2.13%
- FMR Investment Management (UK) Ltd.0.21%
- Nordea Investment Management AB0.20%
- Moneta Asset Management SAS0.17%
Share of the company, as of September 25, 2026
Leadership
- Jean-Christophe Tellier — CEO & Executive Director, 66
- Sandrine Dufour CFA — Executive VP & CFO, 59
- Alistair Henry — Executive VP & Chief Scientific Officer, 58
- Jean-Luc Fleurial — Executive VP & Chief Human Resources Officer, 60
- Fiona Du Monceau — Executive VP of Patient Impact & Chief Commercial Officer, 47
In the news
How much revenue does UCB SA make?
UCB SA reported 7.74 billion EUR in revenue for fiscal year 2025, up 25.8% from 6.15 billion EUR in fiscal year 2024.
Where does UCB SA make most of its revenue?
United States: 63% of revenue by region in fiscal year 2025, followed by International Markets (8%).
What companies are similar to UCB SA?
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Hyloris Pharmaceuticals SA (HYL.BR).
How has UCB SA's revenue changed over the last 5 fiscal years?
Revenue by fiscal year: FY2021, 5.78 billion EUR; FY2022, 5.52 billion EUR; FY2023, 5.25 billion EUR; FY2024, 6.15 billion EUR; FY2025, 7.74 billion EUR.
How has UCB SA's revenue by region changed?
Share of revenue by region in fiscal years 2024 and 2025: United States, 54% and 63%; International Markets, 10% and 8%; Europe Other, 7% and 6%; Germany, 7% and 6%; Japan, 5% and 4%; Spain, 4% and 4%; France, 3% and 3%; Italy, 3% and 3%; U.K. and Ireland, 3% and 2%; Belgium, 1% and 1%; China, 3% and under 1%.
Company Information
Contact & Links
Data as of .
How to cite: DataPorium, “UCB SA (UCB.BR)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/UCB.BR